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Objectives. To estimate the probabilistic cost-effectiveness analysis of cascade screening 
methods in people suspected of Familial Hypercholesterolaemia (FH) from the UK National 
health Health service Service perspective. 
Design. Economic evaluation (Cost Utility analysis) comparing four cascade screening 
strategies for FH: 1. Using LDL-C measurements to diagnose affected relatives (Cholesterol 
method); 2. Cascading only in patients with a causative mutation identified and using DNA 
tests to diagnose relatives (DNA method); 3. DNA testing combined with LDL-C testing in 
families with no mutation identified, only in patients with clinically defined “Definite” FH 
(DNA+DFH method); 4. DNA testing combined with LDL-C testing in no-mutation families 
of both “Definite” and “Probable” FH patients (DNA+DFH+PFH ). A probabilistic model 
was constructed to estimate the treatment benefit from statins, with all diagnosed individuals 
receiving high intensity statin treatment.   
Setting. United Kingdom 
Population. A cohort of 1000 people suspected of having FH aged 50 years for index cases 
and 30 years for relatives, followed for a lifetime. 
Main outcomes. Costs, quality adjusted life years (QALYs) and incremental cost-
effectiveness ratios (ICERs) 
Results. The DNA+DFH+PFH method was the most cost-effective cascade screening 
strategy. The ICER was estimated at £3,666/QALY. Using this strategy, of the tested relatives 
30.6% will be true positives, 6.3% false positives, 61.9% true negatives and 1.1% false 
negatives. Probabilistic sensitivity analysis showed that this approach is 100% cost-effective 
using the conventional benchmark for cost-effective treatments in the NHS of between 
£20,000 and £30,000 per QALY gained.  
Conclusion. Cascade testing of relatives of patients with DFH and PFH is cost-effective 
when using a combination of DNA testing for known family mutations and LDL-C levels in 
the remaining families. The approach is more cost-effective than current primary prevention 
screening strategies.  
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Familial hypercholesterolemia (FH) is characterized by hypercholesterolemia, xanthomas, 
and premature coronary heart disease (CHD) and affects  around 1 in 500 people in western 
countries
 1, 2
.  It is a monogenic disorder caused by mutations in three genes: those coding for 
the receptor for low density lipoprotein (LDL) particles (LDLR), for apolipoprotein B (APOB) 
and for an enzyme involved in the degradation of the receptor as it recycles, PCSK9
3
. 
Treatment with statins is effective and reduces mortality4,5. In the UK less than 15% of the 
predicted 110,000 affected people are diagnosed6.   
FH is  diagnosed in the UK using the Simon Broome Criteria
2,7
 based on cholesterol levels 
(typically the ninety-fifth percentile of total serum cholesterol or LDL-cholesterol (LDL-C) is 
a cut-off value), family history of hyperlipidaemia or early CHD, and presence of (or family 
history of) xanthomas.  Individuals fulfilling these criteria, and those found to carry an FH-
causing mutation are given the diagnosis of definite FH (DFH), while those showing only 
elevated cholesterol levels together with a family history of hyperlipidaemia or early CHD are 
given the diagnosis of possible FH (PFH).   
There is considerable overlap in the distribution of LDL-C levels between individuals with 
and without FH. In children, where the overlap is least
8,9
,  using a simple cut off results in a 
false positive rate of 8-10% and a false negative rate of 10-15%. In adults, the false negative 
is greater10.  Also, an individual‟s cholesterol levels may fluctuate, moving from below to 
above the cut-off value on repeat measurements.  Thus, some patients will be given a false 
negative diagnosis (i.e. told that they do not have FH when they do), while others will be 
given a false positive diagnosis (told that they have FH when they do not).  
When DNA testing is used to diagnose FH, a mutation can be identified in 60-90% of DFH 
patients11, 12, depending on the sensitivity of the methods and the population under 
consideration. By comparison, a mutation can be identified in only 20-30% of PFH patients13,.  
Once the underlying mutation has been identified, molecular genetic screening of first degree 
relatives has a sensitivity and specificity close to 100%. 
The UK National Institute for Health and Clinical Excellence (NICE) has recommended, 
based on deterministic economic evaluation of the alternative approaches to cascade 
screening
14,15,  the use of “cascade screening” of first degree relatives of patients with FH 
using cholesterol measurement and DNA methods in combination. This paper presents the 
results of a probabilistic economic analysis to compare the costs and benefits of alternative 





Model structure, assumptions and analytical methods  
We constructed a decision tree in Excel™  where a hypothetical 1000 patients referred from 
general practice with a suspicion of heterozygous FH entered the model. Figure 1 shows a 
schematic presentation of the decision problem and a full breakdown of the decision 
pathways. The decision pathways for all the methods under consideration each have three 
disease states which depict the initial diagnosis i.e. definite FH, possible FH and not FH, as 
defined by the Simon Broome7 and the FHCAP study 16.  Subsequent branches of the tree are 
dependent on the cascade screening method under consideration which are described in detail 
below. Once individuals are identified as true positives (TP), false positives (FP), true 
negatives (TN) and false negatives (FN) at the end of the decision tree, they enter into a 
Markov model according to the treatment protocol also described below. Four cascade 
screening methods were compared: 
 
1. The cholesterol method: This is the standard method of clinical diagnosis and 
identification of affected relatives using elevation of LDL-C levels. Only patients 
meeting the criteria of DFH or PFH were included for cascade testing.  
2. The DNA method:  The identification of an FH-causing mutation by molecular genetics 
methods, firstly in the index patient and then in first degree relatives. Only patients with 
an identified FH-causing mutation were included for cascade testing.  
3. The DNA+DFH method: Following DNA testing of the index cases cascade testing of 
relatives is undertaken in all mutation-positive index cases but additionally, in the 
relatives of DFH index cases where no mutation can be found, cascade testing is 
undertaken using cholesterol (LDL-C) levels to identify affected relatives  
4. The DNA+DFH+PFH method: Following DNA testing of the index cases cascade 
testing of relatives is undertaken in all mutation-positive index cases but additionally, in 
the relatives of DFH  and PFH index cases where no mutation can be found, cascade 
testing is undertaken using cholesterol (LDL-C) levels to identify affected relatives. 
Treatment protocol and estimated long-term benefits from statin treatment. 
All index cases and relatives with a diagnosis of FH (whether DFH or PFH) are assumed to be 
offered high intensity statin therapy, in line with NICE guideline on FH14, while true and false 
negatives were assumed to be on low intensity statin. For the relatives, a proportion (1.3%) 
30
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  of the subjects with either a true negative or a false negative diagnosis will require 
treatment with low intensity statins, because the combination of their lipid and other 
cardiovascular risk factors brings their 10 year CVD risk to >20% .  False positives were 
given high intensity statin but did not benefit from the statin, rather they incurred a disutility 
(reduction in quality of life) estimated to be about 3% and then varied in sensitivity analysis 
(Expert opinion).  We developed a Markov model using Microsoft™ Excel to estimate the 
treatment benefit from statins. The structure of the model is described in detail previously 1818, 
and used data from the Simon Broome Study 7, 1919. Death from other causes was assumed to 
be the same as that of the general population and was taken from the life tables of the England 
and Wales Government Actuary Department (2006)
 20
. The model assumes that risk of 
cardiovascular disease (CVD) increases with age for both males and females. 
201
. The risk of 
stroke and peripheral artery disease were assumed to be the same as seen in the general 
population, because data from the Simon Broome Register indicated that these risks are not 
significantly higher in the FH population22 Treatment effects of statins were taken from a 
meta-analysis of the four trials that compared high intensity statins with low intensity statins 
after myocardial infarction – see Ttable 3213,242,23,245,26. 
 
Cost data  
Drug costs were taken from the BNF25 BNF 27 (number 5961, 20102011) and are shown in 
supplementary table Table 5. Costs of full fasting and non-fasting cholesterol measurements 
and costs of CVD events were taken from NHS reference costs26costs28,2729. All costs were at 
2009 2010/11 prices and as per current NICE guidance; an annual discount rate of 3.5% was 
used for both costs and health benefits.  
 
Outcomes and quality of life (Utility):  
Clinical outcomes modelled were myocardial infarction, stroke, heart failure, transient 
ischaemic attack; peripheral arterial disease, unstable angina, revascularisation, cardio-
vascular and total mortality. Utility weights for the various health states and age adjusted 
utility from were taken from our earlier study 
1818
. Age adjusted utility was solicited from the 




 (see supplementary table Table 2 and 3). The 
beneficial value of health outcomes was estimated using the Quality Adjusted Life Year 
(QALY). We did not allow for any harmful effects of treatment with statins since significant 
side-effects are relatively uncommon especially in high risk populations
3128
 but assessed their 
impact in sensitivity analysis. 
 
Probabilistic sensitivity analysis  
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Due to imperfect information on the effectiveness of intervention and the resources consumed 
for treatment, both the costs and effects of health interventions are inevitably associated with 
some degree of uncertainty, and this introduces the possibility of error into decision-making 
2932. In our analysis we used Monte Carlo simulation to generate the sampling distribution of 
the joint mean cost and efficacy in order to quantify the uncertainty around the estimates of 
costs and effects. In addition we also did one-way sensitivity analysis on variables which had 
uncertain estimates and yet were likely to influence overall conclusions. These included the 
cost of the cholesterol method, a reduction in the cost of statins, any potential loss in quality 
of life due to side effects of high dose statins and the costs of DNA testing.  
 
Results  
The four cascade screening methods identified differing numbers of true and false negatives 
and positives amongst both cases and relatives (Table 1). The DNA only strategy required the 
least number of relatives to be tested, but did not identify as many true positives as the 
DNA+DFH+PFH strategy. This last strategy was also the strategy that required the largest 
number of relatives to be screened.  
 
Costs of diagnosis and treatment 
Table 2 shows the cost of diagnosis and treatment of people diagnosed with either monogenic 
or polygenic hypercholesterolaemia for each of the four strategies, using the treatment 
protocol outlined above in the methods section, while Table 3 shows the QALYs gained in 
each strategy.  The total costs of diagnosis for the index case included the total cost of clinical 
confirmation for index cases (lipid profile + health care professional costs, estimated to be 
£240 per index case and £139 per relative) and the cost of DNA testing. The cost per relative 
included the costs of sending out letters. These costs were multiplied by the numbers of 
people tested under each strategy.  DNA testing and cascading was not done in those 100 
individuals identified in each strategy as true negatives. 
The cost of treatment and QALY gain per individual was estimated from the Markov model 
for each strategy under consideration. The number of index and relative cases identified by 
each strategy was multiplied by the cost and QALY gain per individual.  Thus the total cost of 
each strategy was the sum of the diagnosis and treatment costs. 
 
Cost effectiveness  
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As shown in Table 4, all DNA based methods were cost-effective relative to the cholesterol 
only method. However, cascade testing from DNA+DFH is ruled out by extended dominance.  
The principle of extended dominance is applied in incremental cost-effectiveness analyses to 
eliminate from consideration strategies whose costs and benefits are improved by a mixed 




. Thus the combinations of DNA only and 
DNA+DFH+PFH are both more cost-effective than DNA+DFH. After accounting for the 
options ruled out by extended dominance, the relevant incremental comparison is between the 
DNA method and the DNA+DFH+PFH method. The estimated base case incremental cost-
effectiveness ratio (ICER) is £3,666/QALY, as shown in Table 4.   
We assessed uncertainty around this ICER by Monte-Carlo simulation using 2000 iterations.  
Figure 2 illustrates the probability that any one strategy is cost-effective, as a function of the 
willingness to pay.  Given a maximum acceptable ceiling ratio of £20,000/QALY the 
probability that DNA+DFH+PFH is cost-effective compared to the DNA method is 100%. 
Thus, given the data, there is a 100% chance that the additional cost of DNA+DFH+PFH, 
compared with the DNA method, is at or below £20,000 per QALY gained.  
One way sensitivity analysis showed that the model results were not sensitive to changes in 
assumptions about loss in quality of life due to side effects of high dose statins as the ICERs 
remained below £20,000/QALY when the assumption was varied between 1% and 10%.  
We also varied the cost of statins as we expect atorvastatin to be off patent in 2011. We thus 
reduced the cost of atorvastatin by 60% and the cost-effectiveness results became more 
favorable with the ICER falling from the current estimate of £3,666 to £3,070/QALY. We 
also varied other variables like the proportions of index cases and relatives who agreed to 
testing, the age at identification for index cases and relatives, and the cost of cholesterol 
testing and DNA costs, and in all cases the ICERs remained below £4,000/QALY, suggesting 
the model is not sensitive to changes in these parameters. The base model assumed that there 
was no quality of life loss associated with side effects of statins, and when we assumed a 5% 
loss in quality of life the ICER increased only slightly to £4,028 demonstrating that the model 




Our economic analysis indicates that the most cost-effective cascade screening strategy for 
people suspected of Familial Hypercholesterolaemia is DNA testing plus cascading from both 
mutation negative definite and possible FH individuals, with an estimated ICER of 
8 
 
£3,666/QALY when compared to the DNA only method. Our results were stable in univariate 
sensitivity analysis. Probabilistic sensitivity analysis also showed that the DNA+DFH+PFH 
strategy is 100% cost-effective as it falls below the recommended £20,000/QALY threshold 
currently used in the UK for evaluating interventions. Altering assumptions about several key 
determinants of cost and effectiveness including the cost of statins (which will fall in the near 
future as some of the potent statins recommended for FH patients come off-patent), the cost 
of DNA testing, the overall cost of the cholesterol measures, the proportions of index cases 
and relatives who agreed to testing, and the age at identification for index cases and relatives 
did not materially influence the ICERs. There is no uncertainty that DNA+DFH +PFH is the 
most cost-effective option.   
 
Strengths and weaknesses 
To our knowledge this is the first probabilistic analysis of FH screening strategies for the UK.  
Because patients with FH have very high LDL-C levels from birth, they will frequently 
require high intensity lipid lowering therapy sufficient to reduce LDL-C to recommended 
levels14,15 and studies have shown that statin treatment reduces their premature mortality5. In 
our model we have used a combination of statins but the model was not sensitive to different 
combinations of statins.  We have assumed that any individual identified with elevated LDL 
cholesterol levels will be treated whether or not they carried the family mutation. Individuals 
who do not carry the mutation are likely to be treated with a lower dose of statin and the costs 
and benefits for this have been included in the model. The results of our model were not 
sensitive to the documented side effects of statins 32 34,35 since variations in screening methods 
influence numbers of people allocated to high or low dose, but have no influence on the 
QALY gain from the statin treatment. 
Because observational data from the Simon Broome Register cohort showed no significant 
increase in mortality in FH patients over 60 years old
4
, we have assumed that people over the 
age of 60 will benefit from statins to the same degree as the general population. This does not 
support ceasing treatment at age 60 in people diagnosed with FH.  People with FH who have 
reached this age or beyond without treatment and without experiencing any cardiovascular 
event or symptoms appear to have a risk low enough not to warrant high intensity treatment, 
that is, a survivor effect.  
Our model did not consider cascade testing from children due to a lack of data on the 
effectiveness of statins in children.  If children were included in the case-finding approach, 
this strategy is likely to become even more cost-effective as the number of relatives per index 
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case would increase. A false-negative diagnosis may deny both the patient who has FH and 
that person‟s relatives with FH the benefit of more intensive cholesterol lowering therapy. By 
contrast, cascade screening from false-positive cases will not identify any true FH patients 
and will waste resources.  It would be possible to reduce the numbers of false positives and 
negatives if better data were available on the range of LDL-C levels to be expected in the 
mutation carrying relatives of patients with FH, and the extent to which this range overlaps 
with that in non-mutation carrying relatives.  
Markov models have inherent limitations. They assume that the probability of an individual 
moving to any given health state in one time period depends only on their current health state 
(there is no longer „memory‟ in the model). Similarly, a patient‟s health outcome and health 
care costs incurred are assumed to depend only on their current health state. These 
assumptions are unlikely to be strictly true, and will tend to underestimate the costs and 
overestimate the health outcomes for CVD events. Thus, interventions that prevent more 
CVD events will appear less cost-effective than they may be in reality.  
 
Comparison with other studies 
Our findings that DNA based screening methods are more cost-effective are consistent with 




 undertook a cost-effectiveness analysis from the 
NHS perspective.  These included universal screening, opportunistic
 
screening in primary 
care, screening of people admitted to hospital
 





patients. They concluded that screening family members was the 
most cost-effective strategy, with an estimated ICER of £3097 per life year gained (LYG) 
using cholesterol measurement for diagnosis and £4914/LYG using DNA testing, while 
universal population screening using cholesterol measurement only was a much less cost-





considered the costs and deaths averted over 10 years from either a population strategy of 
screening 16 year olds or tracing family members of affected patients.   They concluded that 
family tracing was again the most efficient strategy, with the cost per death averted being 
£3187.  A cost-effectiveness study of the FH genetic screening programme in the Netherlands 
resulted in a similar cost per life-year gained of US$ 8, 800 
3538
.  The result was sensitive to 
the price of statin treatment and the number of life-years gained.   
Our results also compares favorably with strategies to identify individuals at a lower risk of 
cardiovascular disease (i.e. primary prevention), which were evaluated in a previous NICE 
guideline in which the recommended screening strategy (targeted screening) has an ICER of 
£7604/QALY36QALY39.  
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Implications and future research 
There is a lack of UK data describing the range of LDL-C levels to be expected in the 
mutation carrying relatives of patients with FH, and the extent to which this range overlaps 
with that in non-mutation carrying relatives. Further research is required to characterise the 
distributions of LDL-C levels in mutation-carrying relatives of patients with FH and the 
extent of overlap with levels in other relatives to improve the performance of screening 
strategies. The cost-effectiveness of DNA screening is likely to improve in the future as the 
proportion of definite FH patients in whom a mutation can be identified increases because of 
improvements in techniques for mutation identification, and also because of the identification 
of new genes where mutations cause FH.  However, even now this economic analysis 
supports the identification and treatment of individuals with FH as a highly cost-effective 
strategy in the prevention of cardiovascular disease.  
 
Conclusion 
National strategies to reduce the burden of cardiovascular disease in the UK would be made 
more effective and more cost effective by incorporating the screening strategy that was 
recommended in national guidance from NICE for the identification and treatment of people 
with Familial Hypercholesterolemia. To date we are not aware that there has been any local 
implementation of such a strategy in England.  
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WHAT IS ALREADY KNOWN ON THIS TOPIC 
Familial Hypercholesterolaemia is a common genetic disorder where patients have a very 
high risk of early onset heart disease that can be effectively treated with high intensity statins. 
Currently in the UK, less than 15% of the predicted 110,000 patients are diagnosed and there 
are no commissioned services to identify people with this condition. Clinical and cost 
effective strategies for the identification of patients with this condition and their 
implementation are urgently required. 
  
WHAT THIS STUDY ADDS 
Cascade testing from index patients with both clinically defined definite and possible FH is 
highly cost-effective when using a combination of DNA testing for the family mutation where 
it can be found and LDL-C levels where it cannot.  Cascade testing to identify relatives of 
patients with FH is also more cost effective than recently recommended primary prevention 
screening strategies. The approach will become even more cost-effective as technological 
advances reduce the cost of DNA testing and increase its sensitivity and following the patent 
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willingness to pay for an extra  unit of health benefits 
Cholesterol method
DNA method
DNA + Chol M-ve DF method




Black and white version 
 
Table 1 Number of index cases and relatives identified by the four cascade strategies 
Outcome Cascade strategies 
 cholesterol DNA DNA+DFH DNA+DFH+PFH 
Cases (N=1000) 
True Positive 480* 420* 450* 480* 
False Negative  0 60 30* 0 
False Positive  420* 420 420 420* 
True Negative 100 100 100 100 
Relatives 
True Positive 765 1338 1385 1433 
False Negative  430 0 27 53 
False Positive  497 0 33 297 
True Negative 2611 1338 1513 2898 
Total relatives 
tested 
4302 2675 2959 4681 
 
* Probands where cascade testing was undertaken 
 
 
Table 2: Costs of diagnosis and treatment for each strategy 
GRAND COSTS Cholesterol DNA 
DNA + Chol 
M-ve DFH 
DNA + Chol M-




















































willingness to pay for an extra  unit of health benefits
Cholesterol method
DNA method
DNA + Chol M-ve DF method
DNA + Chol M-ve DF +PFH method
24 
 
Total cost of diagnosis £839 £1,240 £1,280 £1,519 
Total cost of treatment £43,737 £49,677 £51,390 £53,280 
Combined total cost £44,576 £50,918 £52,670 £54,799 
 
 
Table 3, QALY gain per strategy* 
  Cholesterol DNA DNA + DFH DNA + DFH +PFH 
Total QALY for index cases 8,544 8,517 8,531 8,548 
Total QALY  for relatives 2,343 15,600 15,754 16,628 
Overall total QALYs 10.89 24.12 24.28 25.18 
 
*The QALY gain per person were derived from the statin treatment as described in 




Table 4 Incremental costs effectiveness ratios of the DNA based methods compared to 










Cholesterol £44,576 10.89       
DNA £50,918 24.12 £6,341 13.23 £479 
DNA + Chol M-ve  DFH £52,670 24.28 - - ED** 
DNA + Chol M-ve DF +PFH £54,799 25.18 £3,881 1.06 £3,666 







Model structure, assumptions and analytical methods  
We assumed that each index case has five first degree relatives available for testing 16 and 
each of these five has two first degree relatives (i.e. second degree relatives of the index case), 
and each of these has two first degree relatives (i.e. third degree relatives of the index case). 
We also assumed that 65% of the first degree relatives and 60% of the second degree relatives 
will agree to be tested. These are high estimates for take up in population screening but are 
based on data from the UK FH Cascade Audit Project FHCAP S1 study where these values 
were 85% and 80% respectively. Finally, to simplify the model we assumed that 50% of the 
tested relatives would be the children of the probands and would be in the age range 18-25 
and the remainder would be the siblings of the probands, with an age range of 45-49 years.   
We assumed that a monogenic cause underlies a diagnosis of FH, that is, a true FH patient is 
someone with a relevant gene mutation. To estimate the proportion of true FH patients in the 
hypothetical 1000 patients referred from general practice, we first used data from FHCAP S1 in 
which 30% of the patients currently being treated in lipid clinics had DFH and 60% had PFH 
while 10% failed to meet either set of criteria. This last group were designated true negative 
and not considered for cascade testing.  Based on reported mutation detection rates, we then 
assumed that that 90% of those identified as DFH had a relevant gene mutation (were true 
FH),  as well as 35% of those identified as PFH; meaning that 48% of our hypothetical cohort 
would be true FH patients ((0.9 x 0.3) +(0.35 x 0.6))  We are unaware of any published data 
to address this directly, and this is an extrapolation from the relative number of mutations 
identified in DFH and PFH patients (see below).  
To estimate the proportion of FH and non-FH relatives that would be identified from true FH 
index cases with the cholesterol method of screening we used data from the UK16 and the 
Netherlands 
10
, which gave an age-averaged estimate of 32% true positives (i.e. had FH and 
were identified), 8% false positives (did not have FH but were identified as having FH), 42% 
true negatives, (did not have FH and were not identified as FH) and 18% false negatives (had 
FH but were not identified as FH)10. From false-positive index cases cascade testing will 
identify no true-positive relatives, but a proportion will be identified as “affected” (i.e. false-
positives) because they have LDL-C levels above the diagnostic cut-offs. Conversely, there 
will be no cascade screening from false negatives, so some true FH relatives will not be 
identified. 
For the DNA strategy, the mutation detection rate was taken to be 80% in the DFH group and 
30% in the PFH group11, 12,13. Cascade testing only takes place from mutation-positive index 
26 
 
cases and results in a 50% detection rate (since FH is a monogenic autosomal dominant 
disorder). However, since current mutation detection methods are not 100% sensitive, a 
proportion of the mutation-negative index cases will be false negatives. For the DFH group 
we assumed that this would be true of half of the 20% negatives in the DFH group, meaning 
that overall 80+10 = 90% of the DFH patients are true positives. For the PFH cases, it was 
assumed that a similar proportion of mutations would not be detected as in the DFH group 
(i.e. for every 8 mutations detected in the PFH group one would be missed so the false 
negative rate in the PFH patients with no detected mutation = 30% x 0.125 = 3.8 mutations 
per 100 patients), and an upper estimate of 7% of the PFH mutation-negative index cases as 
false negatives was used. 
For the DNA+DFH strategy, as well as mutation positive index cases, cascade testing is 
additionally undertaken using cholesterol (LDL-C) diagnostic cut-offs in the 20% of patients 
in whom no mutation has been detected (DFH). The proportions of true- and false-positive 
diagnoses from this group were estimated as in the cholesterol method. Similarly, for the 
DNA+DFH+PFH strategy, cascade testing is undertaken using cholesterol (LDL-C) 
diagnostic cut-offs in the additional group of  non-mutation-detected PFH index cases.  
Treatment protocol and estimated long-term benefits from statin treatment. 
All index cases and relatives with a diagnosis of FH (whether DFH or PFH) are assumed to be 
offered high intensity statin therapy, in line with NICE guideline on FH
14
.  A proportion of 
those in the DNA-based strategies who do not carry the family mutation will qualify for low 
intensity statin treatment based on current NICE guidelines of having a >20% 10 year risk of 
CVD18CVD 21. The proportion of such individuals was estimated from data extracted from the 
Health Survey for England 2003 (Dr Tom Marshall, personal communication). The 
proportion of such individuals under 40 years is predicted to be 0%. In those aged 40-44 
years, it is predicted to be 0.7% in men and 0% in women and in those aged 45-49 years 4.7% 
in men and 0.4% in women. Since the model includes equal numbers of men and women the 
average number needing low intensity statin treatment will be 2.6% in those aged 45-49 
years. Given that the model is based on equal number of relatives in the 18-25 and 45-49 year 
age range, overall we predict that 1.3% 
17 
of relatives will qualify for low intensity statin. 
Treatment protocol and estimated long-term benefits from statin treatment. 
We developed a Markov model using Microsoft™ Excel to estimate the treatment benefit 
from statins. The structure of the model is described in detail previously 
18
. Data from the 
Simon Broome database has shown that, compared to the general population, for patients with 
FH aged below 40 years the relative risk of a cardiovascular event can be as high as 100-fold 
7. For those aged 40-59 years the risk falls to about 4- fold and for those aged over 60 years 
27 
 
the risk is 1.2. In the model we have increased the risk of having a cardiovascular even event 
by 100, 4 and 1.2 for ages <40 years, 40-59 years and over 60 years respectively for definite 
FH patients. For relatives who have elevated cholesterol but do not have FH (false positives) 
their risk was assumed to be 20% more than the general population and to be the same across 
all age groups. The risk of stroke and peripheral artery disease were assumed to be the same 
as seen in the general population, because data from the Simon Broome Register indicated 
that these risks are not significantly higher in the FH population19population22. Death from 
other causes was assumed to be the same as that of the general population and was taken from 
the life tables of the England and Wales Government Actuary Department (2006) 20. The 
model assumes that risk of cardiovascular disease (CVD) increases with age for both males 
and females. The rate of CVD increase used in the model was 0.02%, which is the average 
between males and females reported in the NICE technology appraisal of statins 
2021
. 
Treatment effects of statins were taken from a meta-analysis of the four trials that compared 
high intensity statins with low intensity statins after myocardial infarction – see table 3 
213,2224,2325,2426
. We do not believe that this is likely to introduce a significant bias, to the 
results, because of the extremely high CHD risk in untreated FH patients which is similar to 
that seen in seen in post MI patients. 
Cost data  




 (number 61, March 2011) and are shown in 
supplementary table 5. The proportions of different statins being used to treat FH patients 
were obtained from clinic data (Dr A Wierzibicki, personal communication). Consultant 
costs, nurse, clerk, and phlebotomist costs were taken from the standard Unit Costs of Health 
and Social Care26Care28. Estimates of time taken by each health care professional were 
provided by the FHCAP study (personal communication). Costs of full fasting and non-





. Cost of DNA testing was £400 and £100 for probands and relatives 
respectively estimated from the FHCAP study (personal communication).  All costs were at 
2010/11 prices and as per current NICE guidance; an annual discount rate of 3.5% was used 
for both costs and health benefits.  
Costs of DNA testing for Index cases and relatives were taken from FHCAP study. The costs 
included the costs of samples; postage in a provided blood-safe GPO recommended container 
and sending back the processed report to the referring clinicians (total estimated costs £20), 
For index cases there are costs related to the three stage genetic testing , and for a detailed 
explanation of the procedures for the 3-stage genetic testing see 
S3
  The three stages are: 1). 
ARMS kit test of 20 common mutations, 2) Sequence of LDLR gene and 3) MLPA analysis 
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for deletions, estimated to be about £380 in total. For relatives the direct test for family 
mutation is estimated to be £80. This gives a total of £400 for index cases (£380 + £20) and 




S1 Hadfield SG, Horara S, Starr BJ et al.  Are patients with familial 
hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the DH 
FH cascade testing project. Ann Clin Biochem. 2008; 45:199-205. 
 




S3 Taylor A, Patel K, Tsedeke J, Humphries SE, Norbury G. Mutation screening in 







Supplementary Table 1, Treatment effect used in the model 








Myocardial infarction  0.81 0.72 0.91 -0.21 0.0610 
Stroke 0.82 0.70 0.96 -0.20 0.0822 
Peripheral artery disease  0.87 0.69 1.00 -0.14 0.0966 
Heart Failure 0.77 0.65 0.92 -0.26 0.0904 
Revascularisation 0.78 0.69 1.00 -0.25 0.0966 
Unstable angina 0.84 0.71 0.86 -0.17 0.0499 
Cardiovascular death 0.92 0.72 1.00 -0.08 0.0855 
Death other causes 1.00 1.00 1.00 1.00 1.0000 
False Positive 0.95 0.90 0.99 -0.05 0.0248 
Log normal distribution was used for treatment effect 
 
 
Supplementary Table 2: Health state utilities uses in the model  
Health state Utility  Distribution (Beta) 
alpha beta 
Well  0.95   
Myocardial infarction (first year) 0.76 427.0919 134.8711 
Myocardial infarction (subsequent) 0.88 285.9348 38.9911 
Stroke (first year) 0.63 91.1103 53.7391 
Stroke (subsequent) 0.63 91.1103 53.7391 
Peripheral artery disease (first year) 0.90 201.6000 22.4000 
Peripheral artery disease (subsequent) 0.90 201.6000 22.4000 
Heart failure 0.68 369.0095 171.2680 
Heart failure (subsequent) 0.68 369.0095 171.2680 
Revascularisation 0.93 31.3118 2.3568 
Revascularisation (subsequent) 0.93 40.9973 3.0858 
Unstable angina (first year) 0.77 420.1158 125.4891 
Unstable angina (subsequent) 0.88 285.9348 38.9911 





Supplementary Table 3, Age specific quality of life 




35-44 0.89 0.005 3484.35 430.65 
45-54 0.85 0.006 3009.57 531.10 
55-64 0.8 0.009 1579.45 394.86 
65-74 0.8 0.008 1999.20 499.80 
75+ 0.76 0.011 1144.89 361.55 
A beta distribution was used 
Source: DH, Health Survey for England, 1996 
The final utility for a health state was age adjusted by multiplying the health state 
utility with the age utility. For instance  
 In general those aged between 45-54 have a utility of 0.85 
 If the person has PAD the health state utility is 0.9 
 Therefore age adjusted utility in this case for a person with PAD would be 
(0.85*0.9)=0.765- this is the figure that will be used in the model 
 
Supplementary Table 4 Costs of cardiovascular events  
Health state Mean 
Cost  
Distribution (Gamma) Source  
alpha beta 
 Myocardial infarction (first 
year) 
£1,705 1 1,705 
NHS ref cost 2008/09 
Myocardial infarction 
(subsequent) 
£500 1 500 
Nherera 2010 
Stroke (first year) £10,812 1 10,812 NHS ref cost 2008/09 
Stroke (subsequent) £2,163 1 2,163 NHS ref cost 2008/09 
Peripheral artery disease (first 
year) 
£2,214 1 2,214 
NHS ref cost 2008/09 
Peripheral artery disease 
(subsequent) 
£264 1 264 
NHS ref cost 2008/09 
Heart failure £1,798 1 1,798 NHS ref cost 2008/09 
Heart failure (subsequent) £500 1 500 Nherera 2010 
Revascularisation £10,941 1 10,941 DH reference cost 
Revascularisation 
(subsequent) 
£500 1 500 
Nherera 2010 
Unstable angina (first year) £1,138 1 1,138 NHS ref cost 2008/09 
Unstable angina (subsequent) £500 1 500 Nherera 2010 




Supplementary Table 5, Cost of drugs and proportions of FH who took various drugs 
Drug 
Proportions of 
FH on drug  
Annual cost  
Weighted drug cost in 
the model** 
Simvastatin 40mg 2% £18 £0.4 
Simvastatin 80mg 9% £43 £4 
Atorvastatin 80mg 64% £368 £235 
Simvastatin 40mg + ezetimibe  4% £436 £17 
Simvastatin 80mg + ezetimibe  11% £537 £59 
Atorvastatin 40mg + ezetimibe 10% £664 £66 
Total drug costs 100%  £382.0 
Drug cost Source: BNF Vol 59 2010 
** Weighted drug cost in the model is a product of the proportions of people on a drug 
multiplied by the annual cost of the drug 
 















GP practice nurse £36.00 2 1 £130.00 £65.00 
Clerk  £17.00 1 0.5 £17.00 £8.50 
Phlebotomist £17.00 0.17 0.17 £2.89 £2.89 
Consultant £178.00 0.75 0.42 £133.50 £74.76 
Non-fasting TC £7.00   
£7.00 £7.00 







Total cost    
£240 £139 
** Weighted cost in the model is a product of the unit cost/hour multiplied by the estimated 
time taken for health care professionals 
 
